Hyperpolarized Carbon-13 MRI for Early Response Assessment of Neoadjuvant Chemotherapy in Breast Cancer Patients.

Autor:	Woitek R; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, United Kingdom.; Department of Radiology, University of Cambridge, Cambridge, United Kingdom.; Department of Radiology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria., McLean MA; Department of Radiology, University of Cambridge, Cambridge, United Kingdom.; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Center, Cambridge, United Kingdom., Ursprung S; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, United Kingdom.; Department of Radiology, University of Cambridge, Cambridge, United Kingdom., Rueda OM; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Center, Cambridge, United Kingdom.; MRC Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom., Manzano Garcia R; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Center, Cambridge, United Kingdom., Locke MJ; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, United Kingdom.; Department of Radiology, University of Cambridge, Cambridge, United Kingdom., Beer L; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, United Kingdom.; Department of Radiology, University of Cambridge, Cambridge, United Kingdom.; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria., Baxter G; Department of Radiology, University of Cambridge, Cambridge, United Kingdom., Rundo L; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, United Kingdom.; Department of Radiology, University of Cambridge, Cambridge, United Kingdom., Provenzano E; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, United Kingdom.; Department of Oncology, Cambridge Breast Cancer Research Unit, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom., Kaggie J; Department of Radiology, University of Cambridge, Cambridge, United Kingdom., Patterson A; Department of Radiology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom., Frary A; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, United Kingdom.; Department of Radiology, University of Cambridge, Cambridge, United Kingdom., Field-Rayner J; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, United Kingdom.; Department of Radiology, University of Cambridge, Cambridge, United Kingdom., Papalouka V; Department of Radiology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom., Kane J; Department of Oncology, Cambridge Breast Cancer Research Unit, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.; Department of Oncology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, England., Benjamin AJV; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, United Kingdom.; Department of Radiology, University of Cambridge, Cambridge, United Kingdom., Gill AB; Department of Radiology, University of Cambridge, Cambridge, United Kingdom., Priest AN; Department of Radiology, University of Cambridge, Cambridge, United Kingdom., Lewis DY; Molecular Imaging Laboratory Cancer Research UK Beatson Institute, Glasgow, United Kingdom.; Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom., Russell R; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Center, Cambridge, United Kingdom., Grimmer A; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, United Kingdom.; Department of Radiology, University of Cambridge, Cambridge, United Kingdom., White B; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, United Kingdom.; Department of Radiology, University of Cambridge, Cambridge, United Kingdom., Latimer-Bowman B; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, United Kingdom.; Department of Radiology, University of Cambridge, Cambridge, United Kingdom., Patterson I; Department of Radiology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom., Schiller A; Department of Radiology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom., Carmo B; Department of Radiology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom., Slough R; Department of Radiology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom., Lanz T; RAPID Biomedical, Rimpar, Germany., Wason J; MRC Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom.; Population Health Sciences Institute, Newcastle University, Newcastle-upon-Tyne, United Kingdom., Schulte RF; GE Healthcare, Munich, Germany., Chin SF; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Center, Cambridge, United Kingdom., Graves MJ; Department of Radiology, University of Cambridge, Cambridge, United Kingdom.; Department of Radiology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom., Gilbert FJ; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, United Kingdom.; Department of Radiology, University of Cambridge, Cambridge, United Kingdom.; Department of Radiology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom., Abraham JE; Department of Oncology, Cambridge Breast Cancer Research Unit, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.; Department of Oncology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, England., Caldas C; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Center, Cambridge, United Kingdom.; Department of Oncology, Cambridge Breast Cancer Research Unit, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.; Department of Oncology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, England., Brindle KM; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Center, Cambridge, United Kingdom.; Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom., Sala E; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, United Kingdom.; Department of Radiology, University of Cambridge, Cambridge, United Kingdom.; Department of Radiology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom., Gallagher FA; Cancer Research UK Cambridge Centre, University of Cambridge, Cambridge, United Kingdom. fag1000@cam.ac.uk.; Department of Radiology, University of Cambridge, Cambridge, United Kingdom.; Department of Radiology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
Jazyk:	angličtina
Zdroj:	Cancer research [Cancer Res] 2021 Dec 01; Vol. 81 (23), pp. 6004-6017. Date of Electronic Publication: 2021 Oct 08.
DOI:	10.1158/0008-5472.CAN-21-1499
Abstrakt:	Hyperpolarized 13 C-MRI is an emerging tool for probing tissue metabolism by measuring 13 C-label exchange between intravenously injected hyperpolarized [1- 13 C]pyruvate and endogenous tissue lactate. Here, we demonstrate that hyperpolarized 13 C-MRI can be used to detect early response to neoadjuvant therapy in breast cancer. Seven patients underwent multiparametric 1 H-MRI and hyperpolarized 13 C-MRI before and 7-11 days after commencing treatment. An increase in the lactate-to-pyruvate ratio of approximately 20% identified three patients who, following 5-6 cycles of treatment, showed pathological complete response. This ratio correlated with gene expression of the pyruvate transporter MCT1 and lactate dehydrogenase A ( LDHA ), the enzyme catalyzing label exchange between pyruvate and lactate. Analysis of approximately 2,000 breast tumors showed that overexpression of LDHA and the hypoxia marker CAIX was associated with reduced relapse-free and overall survival. Hyperpolarized 13 C-MRI represents a promising method for monitoring very early treatment response in breast cancer and has demonstrated prognostic potential. SIGNIFICANCE: Hyperpolarized carbon-13 MRI allows response assessment in patients with breast cancer after 7-11 days of neoadjuvant chemotherapy and outperformed state-of-the-art and research quantitative proton MRI techniques. (©2021 The Authors; Published by the American Association for Cancer Research.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu